Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.47 |
| ▸ | MLYCD | O95822 | 3/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3956492 | 0.88 | EGLN1 (0.50) | RORCSMN1; SMN2KDREGLN1TRPV1 | |
| SCHEMBL445818 | 0.88 | EGLN1 (0.62) | SMN1; SMN2KDREGLN1TRPV1PTGS1 | |
| SCHEMBL4969614 | 0.86 | KMT2A (0.54) | PTGS1KDM4EKMT2AALDH1A1 | |
| SCHEMBL444553 | 0.84 | TRPV1 (0.60) | TRPV1KDM4E | |
| SCHEMBL5422708 | 0.83 | KMT2A (0.46) | RORCKDREGLN1TRPV1KDM4E | |
| SCHEMBL4600539 | 0.82 | KMT2A (0.63) | KDRKDM4EKMT2ANAPRTPRKCI | |
| SCHEMBL12334586 | 0.81 | RORC (0.72) | RORCSMN1; SMN2MLYCDPTGS1KDM4E | |
| SCHEMBL4599740 | 0.80 | PRKCI (0.67) | KDREGLN1KDM4EKMT2ANAPRT | |
| SCHEMBL31077989 | 0.80 | SMN1; SMN2 (0.63) | RORCSMN1; SMN2KDRTRPV1MLYCD | |
| SCHEMBL447449 | 0.79 | NAPRT (0.51) | KDRKDM4EKMT2ANAPRTPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-1971604-B1 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1971604-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | Amgen Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007048070-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185171-A1 | Compounds and methods of use | VHL, PGF, PTGIS | RORC 1276/4885SMN1; SMN2 2119/4885KDR 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.